Last reviewed · How we verify
NCT02769091: NASH
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
Phase 2 trial testing TEV-45478 in Nonalcoholic Steatohepatitis. Withdrawn.
31 January 2018
Quick facts
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 30 September 2016 |
| Primary completion | 31 January 2018 |
| Estimated completion | 28 February 2018 |
Drugs / interventions tested
- TEV-45478 — full drug profile →
- Placebo
Conditions studied
- Nonalcoholic Steatohepatitis — all drugs for Nonalcoholic Steatohepatitis →
- Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Nonalcoholic Steatohepatitis or Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02769091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nonalcoholic Steatohepatitis
Currently open trials in the same condition.
- NCT07481734 — Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) · Phase 2 · recruiting
- NCT06465186 — A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) · Phase 2 · active not recruiting
- NCT05526144 — Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans · Phase 2 · recruiting
- NCT05330923 — Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease · recruiting
- NCT04550481 — Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study · Phase 2 · active not recruiting
Other Teva Branded Pharmaceutical Products R&D, Inc. trials
Trials by the same sponsor.
- NCT06664619 — A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate · Phase 3 · recruiting
- NCT06627231 — Mass Balance Clinical Trial With TEV-56286 · Phase 1 · completed
- NCT06480552 — An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Co · Phase 1 · recruiting
- NCT06290102 — Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluti · Phase 1 · completed
- NCT06253546 — Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02769091 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Teva Branded Pharmaceutical Products R&D, Inc.
- Last refreshed: 9 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02769091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing